{"id":55535,"date":"2026-01-26T21:52:33","date_gmt":"2026-01-26T13:52:33","guid":{"rendered":"https:\/\/flcube.com\/?p=55535"},"modified":"2026-01-26T21:52:34","modified_gmt":"2026-01-26T13:52:34","slug":"knature-biopharm-files-hong-kong-ipo-backed-by-nad-mitochondrial-platform","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=55535","title":{"rendered":"Knature Biopharm Files Hong Kong IPO Backed by NAD+ Mitochondrial Platform"},"content":{"rendered":"\n<p><strong>Knature Biopharmaceutical Co., Ltd.<\/strong> announced it has filed for an <strong>initial public offering (IPO)<\/strong> with the <strong>Hong Kong Stock Exchange<\/strong>, seeking to raise capital to expand its <strong>mitochondrial medicine portfolio<\/strong> anchored by <strong>coenzyme I<\/strong>, the <strong>only domestically developed NAD+ therapy<\/strong> approved in China. The company reported <strong>RMB\u202f238\u202fmillion (USD\u202f34\u202fmillion)<\/strong> in sales for the first nine months of 2025.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-ipo-overview\">IPO Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Knature Biopharmaceutical Co., Ltd. (China-based)<\/td><\/tr><tr><td><strong>Exchange<\/strong><\/td><td>Hong Kong Stock Exchange<\/td><\/tr><tr><td><strong>Filing Date<\/strong><\/td><td>Week of 20\u202fJan\u202f2026<\/td><\/tr><tr><td><strong>Offer Price<\/strong><\/td><td>Undisclosed<\/td><\/tr><tr><td><strong>Use of Proceeds<\/strong><\/td><td>R&amp;D expansion, manufacturing scale-up, commercialization of mitochondrial therapies<\/td><\/tr><tr><td><strong>Financial Advisor<\/strong><\/td><td>Undisclosed<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-company-profile-amp-mitochondrial-focus\">Company Profile &amp; Mitochondrial Focus<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Therapeutic Focus:<\/strong> <strong>Mitochondrial medicine<\/strong> targeting diseases caused by <strong>mitochondrial dysfunction<\/strong>, including <strong>cardiovascular diseases, neurodegenerative disorders, reproductive health, and aging<\/strong><\/li>\n\n\n\n<li><strong>Platform Technology:<\/strong> <strong>NAD+ (nicotinamide adenine dinucleotide) biology<\/strong> \u2013 coenzyme I represents the <strong>first and only domestically developed NAD+ therapy<\/strong> in China with <strong>national and global approvals<\/strong><\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> NAD+ is a critical coenzyme for cellular energy metabolism; Knature\u2019s therapies aim to <strong>restore mitochondrial function<\/strong> in conditions characterized by energy failure<\/li>\n\n\n\n<li><strong>Clinical Applications:<\/strong> Cardiovascular protection, immune modulation, anti-aging interventions<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-commercial-portfolio\">Commercial Portfolio<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Category<\/th><th>Key Products<\/th><th>Indications<\/th><th>Status<\/th><\/tr><\/thead><tbody><tr><td><strong>Flagship NAD+ Therapy<\/strong><\/td><td><strong>Coenzyme I<\/strong><\/td><td>Cardiovascular diseases, immune disorders<\/td><td><strong>Marketed<\/strong> (China + global)<\/td><\/tr><tr><td><strong>Ophthalmology\/Orthopedics<\/strong><\/td><td>Hyaluronidase<\/td><td>Tissue permeability, joint mobility<\/td><td>Marketed<\/td><\/tr><tr><td><strong>Circulatory System<\/strong><\/td><td>Pancreatic kininogenase<\/td><td>Microcirculation improvement<\/td><td>Marketed<\/td><\/tr><tr><td><strong>Cardiovascular<\/strong><\/td><td>Nitroprusside<\/td><td>Hypertensive emergencies<\/td><td>Marketed<\/td><\/tr><tr><td><strong>Generics (16 products)<\/strong><\/td><td>Digestive, respiratory, hematological, nervous system drugs<\/td><td>Various<\/td><td>Marketed<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Total Commercialized Drugs:<\/strong> <strong>20 products<\/strong> across <strong>mitochondrial medicine and established therapeutic areas<\/strong><\/li>\n\n\n\n<li><strong>Revenue Mix:<\/strong> Coenzyme I contributes <strong>~45%<\/strong> of total sales; generics provide <strong>stable cash flow<\/strong> for R&amp;D investment<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-performance\">Financial Performance<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>9M\u202f2025<\/th><th>FY\u202f2024 (Est.)<\/th><\/tr><\/thead><tbody><tr><td><strong>Revenue<\/strong><\/td><td>RMB\u202f238\u202fmillion (USD\u202f34\u202fmillion)<\/td><td>~RMB\u202f310\u202fmillion<\/td><\/tr><tr><td><strong>Growth Rate<\/strong><\/td><td>28\u202f% YoY<\/td><td>22\u202f% YoY<\/td><\/tr><tr><td><strong>Gross Margin<\/strong><\/td><td>68\u202f%<\/td><td>65\u202f%<\/td><\/tr><tr><td><strong>R&amp;D Investment<\/strong><\/td><td>RMB\u202f42\u202fmillion (18\u202f% of revenue)<\/td><td>RMB\u202f55\u202fmillion<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-amp-competitive-landscape\">Market Opportunity &amp; Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>China<\/th><th>Global<\/th><\/tr><\/thead><tbody><tr><td><strong>Mitochondrial Disease Patients<\/strong><\/td><td>12\u202fmillion<\/td><td>65\u202fmillion<\/td><\/tr><tr><td><strong>NAD+ Therapy Market (2030E)<\/strong><\/td><td>\u00a515\u202fbillion<\/td><td>$8.5\u202fbillion<\/td><\/tr><tr><td><strong>Aging-Related Mitochondrial Dysfunction<\/strong><\/td><td>180\u202fmillion<\/td><td>900\u202fmillion<\/td><\/tr><tr><td><strong>Addressable Market<\/strong><\/td><td>\u00a528\u202fbillion<\/td><td>$22\u202fbillion<\/td><\/tr><tr><td><strong>Knature Peak Revenue (2032E)<\/strong><\/td><td>\u00a52.8\u202fbillion<\/td><td>$450\u202fmillion<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Key Competitors:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>ChromaDex<\/strong> (Niagen\/NMN supplements) \u2013 Nutraceutical approach, limited clinical validation<\/li>\n\n\n\n<li><strong>Elysium Health<\/strong> (Basis) \u2013 Consumer NAD+ precursor, not pharmaceutical grade<\/li>\n\n\n\n<li><strong>Knature<\/strong> \u2013 <strong>Only pharmaceutical-grade NAD+ therapy<\/strong> (coenzyme I) with <strong>regulatory approvals<\/strong> and <strong>clinical evidence<\/strong> in China<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-positioning\">Strategic Positioning<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Manufacturing:<\/strong> <strong>Shanghai facility<\/strong> (GMP certified) produces coenzyme I for domestic and export markets; <strong>capacity expansion<\/strong> planned to meet growing demand for mitochondrial therapies<\/li>\n\n\n\n<li><strong>R&amp;D Pipeline:<\/strong> <strong>4 IND-enabling programs<\/strong> targeting <strong>neurodegenerative diseases<\/strong> (Parkinson\u2019s, Alzheimer\u2019s) and <strong>cardiac mitochondrial dysfunction<\/strong><\/li>\n\n\n\n<li><strong>Global Expansion:<\/strong> Coenzyme I already approved in <strong>Southeast Asia and Latin America<\/strong>; IPO proceeds will fund <strong>FDA IND filing<\/strong> for US market entry<\/li>\n\n\n\n<li><strong>Differentiation:<\/strong> <strong>First-mover advantage<\/strong> in <strong>pharmaceutical-grade NAD+ therapy<\/strong> in China; established <strong>hospital formulary presence<\/strong> (800+ tier\u20112\/3 hospitals)<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding IPO completion, market penetration, and revenue forecasts for Knature\u2019s mitochondrial medicine portfolio. Actual results may differ due to market conditions, regulatory review timelines, and competitive dynamics in the NAD+ therapy space.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/sehk26012500333_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of sehk26012500333_c.\"><\/object><a id=\"wp-block-file--media-e3f6d5b6-3625-477b-973b-710f02a81f1f\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/sehk26012500333_c.pdf\">sehk26012500333_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/sehk26012500333_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-e3f6d5b6-3625-477b-973b-710f02a81f1f\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Knature Biopharmaceutical Co., Ltd. announced it has filed for an initial public offering (IPO) with&#8230;<\/p>\n","protected":false},"author":1,"featured_media":55539,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[72,4575],"class_list":["post-55535","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-ipo","tag-knature-biopharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Knature Biopharm Files Hong Kong IPO Backed by NAD+ Mitochondrial Platform - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Knature Biopharmaceutical Co., Ltd. announced it has filed for an initial public offering (IPO) with the Hong Kong Stock Exchange, seeking to raise capital to expand its mitochondrial medicine portfolio anchored by coenzyme I, the only domestically developed NAD+ therapy approved in China. The company reported RMB\u202f238\u202fmillion (USD\u202f34\u202fmillion) in sales for the first nine months of 2025.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=55535\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Knature Biopharm Files Hong Kong IPO Backed by NAD+ Mitochondrial Platform\" \/>\n<meta property=\"og:description\" content=\"Knature Biopharmaceutical Co., Ltd. announced it has filed for an initial public offering (IPO) with the Hong Kong Stock Exchange, seeking to raise capital to expand its mitochondrial medicine portfolio anchored by coenzyme I, the only domestically developed NAD+ therapy approved in China. The company reported RMB\u202f238\u202fmillion (USD\u202f34\u202fmillion) in sales for the first nine months of 2025.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=55535\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-26T13:52:33+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-26T13:52:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2603.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55535#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55535\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Knature Biopharm Files Hong Kong IPO Backed by NAD+ Mitochondrial Platform\",\"datePublished\":\"2026-01-26T13:52:33+00:00\",\"dateModified\":\"2026-01-26T13:52:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55535\"},\"wordCount\":494,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55535#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/2603.webp\",\"keywords\":[\"IPO\",\"Knature Biopharmaceutical\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55535#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55535\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=55535\",\"name\":\"Knature Biopharm Files Hong Kong IPO Backed by NAD+ Mitochondrial Platform - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55535#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55535#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/2603.webp\",\"datePublished\":\"2026-01-26T13:52:33+00:00\",\"dateModified\":\"2026-01-26T13:52:34+00:00\",\"description\":\"Knature Biopharmaceutical Co., Ltd. announced it has filed for an initial public offering (IPO) with the Hong Kong Stock Exchange, seeking to raise capital to expand its mitochondrial medicine portfolio anchored by coenzyme I, the only domestically developed NAD+ therapy approved in China. The company reported RMB\u202f238\u202fmillion (USD\u202f34\u202fmillion) in sales for the first nine months of 2025.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55535#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55535\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55535#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/2603.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/2603.webp\",\"width\":1080,\"height\":608,\"caption\":\"Knature Biopharm Files Hong Kong IPO Backed by NAD+ Mitochondrial Platform\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55535#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Knature Biopharm Files Hong Kong IPO Backed by NAD+ Mitochondrial Platform\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Knature Biopharm Files Hong Kong IPO Backed by NAD+ Mitochondrial Platform - Insight, China&#039;s Pharmaceutical Industry","description":"Knature Biopharmaceutical Co., Ltd. announced it has filed for an initial public offering (IPO) with the Hong Kong Stock Exchange, seeking to raise capital to expand its mitochondrial medicine portfolio anchored by coenzyme I, the only domestically developed NAD+ therapy approved in China. The company reported RMB\u202f238\u202fmillion (USD\u202f34\u202fmillion) in sales for the first nine months of 2025.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=55535","og_locale":"en_US","og_type":"article","og_title":"Knature Biopharm Files Hong Kong IPO Backed by NAD+ Mitochondrial Platform","og_description":"Knature Biopharmaceutical Co., Ltd. announced it has filed for an initial public offering (IPO) with the Hong Kong Stock Exchange, seeking to raise capital to expand its mitochondrial medicine portfolio anchored by coenzyme I, the only domestically developed NAD+ therapy approved in China. The company reported RMB\u202f238\u202fmillion (USD\u202f34\u202fmillion) in sales for the first nine months of 2025.","og_url":"https:\/\/flcube.com\/?p=55535","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-26T13:52:33+00:00","article_modified_time":"2026-01-26T13:52:34+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2603.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=55535#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=55535"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Knature Biopharm Files Hong Kong IPO Backed by NAD+ Mitochondrial Platform","datePublished":"2026-01-26T13:52:33+00:00","dateModified":"2026-01-26T13:52:34+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=55535"},"wordCount":494,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=55535#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2603.webp","keywords":["IPO","Knature Biopharmaceutical"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=55535#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=55535","url":"https:\/\/flcube.com\/?p=55535","name":"Knature Biopharm Files Hong Kong IPO Backed by NAD+ Mitochondrial Platform - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=55535#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=55535#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2603.webp","datePublished":"2026-01-26T13:52:33+00:00","dateModified":"2026-01-26T13:52:34+00:00","description":"Knature Biopharmaceutical Co., Ltd. announced it has filed for an initial public offering (IPO) with the Hong Kong Stock Exchange, seeking to raise capital to expand its mitochondrial medicine portfolio anchored by coenzyme I, the only domestically developed NAD+ therapy approved in China. The company reported RMB\u202f238\u202fmillion (USD\u202f34\u202fmillion) in sales for the first nine months of 2025.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=55535#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=55535"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=55535#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2603.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2603.webp","width":1080,"height":608,"caption":"Knature Biopharm Files Hong Kong IPO Backed by NAD+ Mitochondrial Platform"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=55535#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Knature Biopharm Files Hong Kong IPO Backed by NAD+ Mitochondrial Platform"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2603.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55535","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=55535"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55535\/revisions"}],"predecessor-version":[{"id":55540,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55535\/revisions\/55540"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/55539"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=55535"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=55535"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=55535"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}